What changed on 15 July 2026?
Deferred payment credit — the interest-free model of twelve or fewer instalments, commonly called buy now, pay later — entered the FCA's perimeter on 15 July 2026, under final rules the regulator published in February 2026. Third-party lenders now need FCA authorisation or a place in the temporary permissions regime. That regime's registration window ran from mid-May to the start of July, with six months from Regulation Day to apply for full authorisation. Lenders must carry out proportionate affordability and creditworthiness assessment before lending. The Consumer Duty applies, and checkouts must disclose payment schedules, amounts and the consequences of missing them.
The market being regulated had grown from about sixty million pounds in 2017 to over thirteen billion by 2024, with roughly one in five UK adults using the product. The FCA's deputy chief executive framed the objective in a single proposition: nobody should be lent to who cannot repay. Agreements made before Regulation Day remain unregulated; everything after runs under the regime.
For most of retail, this is a consumer-protection story heading the right way. For pharmacy it opens a harder question. Regulation confers respectability, and newly authorised lenders will market their healthcare credentials into every vertical with high order values. The checkout they will most want to occupy is the one this site has spent recent weeks describing: the private treatment plan priced in monthly hundreds.
Why is pharmacy tempted?
Because the arithmetic flatters every party at the point of sale. The oral GLP-1 analysis mapped a category with ongoing prices from £154 to £269 a month and introductory offers engineered to convert. Travel clinics invoice families in the hundreds, and TRT and hair-loss plans run to four figures a year.
Against figures of that order, an instalment button measurably improves conversion and average order value. The providers' materials say so because it is true. A pharmacy watching its checkout abandonment has a genuine commercial problem, and this product genuinely addresses it. Add the competitive dynamic — a chain offering instalments converts the stretched patient a pharmacy without them loses. The temptation is not foolishness. It is ordinary commercial reasoning, applied to a product category where, this article argues, ordinary commercial reasoning is the wrong instrument.
What is the debt-treatment entanglement?
Placing credit beneath a medicine breaks three separations that healthcare's design otherwise maintains. Adherence acquires a repayment schedule: a patient mid-titration whose instalment fails is managing a clinical taper and a collections process arising from one cause. The adherence literature consistently finds that treatment discipline fails at the point of financial stress — precisely when the instalment model adds fees. The vulnerable are the target market by construction: this site's demand analysis found the financially stretched already misstating measurements and buying through informal channels to obtain these medicines. A credit facility at the checkout does not create new affluent demand. It recruits exactly the cohort for whom price was the barrier — the cohort affordability assessment exists to protect. And the clinical relationship acquires a creditor: once a lender sits inside the transaction, the pharmacy's patient is also a debtor for the treatment itself, and the service's incentives around retention and renewal now compound with a financing partner's. A medicine supplied on instalments is a treatment plan with a default clause. An interest-free label does not change what defaults do to those who incur them.
What does regulation resolve, and what can it not?
The new regime fixes genuine harms, and deserves acknowledgement for it. Affordability assessment addresses the preceding era of unassessed lending. The Consumer Duty compels outcome monitoring. Checkout disclosure ends any pretence that instalments are not debt. Ombudsman access gives those treated unfairly a route, and an authorisation gate carrying criminal consequences shuts out the least scrupulous operators. If pharmacy patients meet this product, this article would rather they met the regulated version — and says so without irony.
What regulation cannot fix is category fit. The FCA regulates how credit is sold, not where it belongs. A fully compliant, affordability-assessed, Consumer-Duty-monitored loan attached to a course of medicine still entangles treatment with debt, still concentrates on the financially stretched, and still puts a default clause inside a clinical relationship. The strongest version of the contrary case — that regulation has made the product safe enough for healthcare — mistakes the objection. The sector's problem was never only that the lending was unregulated. It was that it was lending. 15 July changed the adjective, not the noun.
What do the counterarguments establish?
An opinion piece owes its opponents their strongest case. Three arguments deserve proper answers.
The access argument says private treatment is expensive, credit widens access, and refusing instalments is gatekeeping by wealth. It is partly right, and the reply is architectural rather than dismissive. Monthly-collected supply delivers an identical monthly outlay without the debt. So the access case for this product resolves into a case for monthly pricing, which this article endorses. What credit adds beyond that is the capacity to owe for treatment already consumed. That is the entanglement, not the access.
The autonomy argument says adults finance holidays and furniture, and paternalism about their medicine spending is not pharmacy's job. But a pharmacy is not neutral retail. The sector holds gatekeeping duties precisely because medicine demand is inelastic, emotionally weighted and clinically consequential. And the autonomy on offer is exercised at a checkout engineered around an urgency the entire service exists to mediate. Respecting patients means not building the pressure they are later held responsible for.
The parity argument says dentistry, optics, veterinary practice and aesthetics finance treatment routinely, so pharmacy's reluctance is inconsistent. The honest answer concedes ground. Finance on a one-off procedure — an implant, a lens — is a materially different thing. The treatment completes at the outset and only the debt continues, and this article's position is not mainly about those. Ongoing medicine supply differs in kind. The treatment and the debt run at the same time, default interrupts a course rather than trailing a completed one, and stopping carries clinical consequences a crown does not. Parity reasoning fails precisely where medicines are most distinctively themselves.
What is the scope position on own-book instalments?
One structural detail needs its own section, because it will otherwise be misread as an invitation. The new perimeter captures deferred payment credit from third-party lenders — where the lender and the supplier of the goods are different persons. A merchant financing its own sales on its own book sits, in general, outside it, as such arrangements did before. A pharmacy could therefore run its own instalment arrangement without becoming an FCA-regulated lender.
Read that as the difficulty it is, not the opportunity it resembles. An own-book arrangement carries the entire entanglement — the failed instalment mid-treatment, the pharmacy collecting from its own patient — with none of the regime's affordability machinery, none of its forbearance rules, and no lender absorbing the credit risk. The whole thing rests on a professional relationship the GPhC's standards govern even where the FCA's do not. The regulated third-party product is at least an unwise arrangement with guardrails. The unregulated own-book version is the same arrangement with the pharmacy holding every exposure. Falling outside scope is a description, not an endorsement.
What do the providers' own rules establish?
A quieter obstacle never appears in the sales materials. The major providers' own acceptable-use and category frameworks have historically restricted medicines and pharmacy. It is the same family of policies this cluster met at Stripe and PayPal, and for comparable reasons: regulated goods, health risk and brand exposure. Where healthcare instalment credit has grown, it has grown at the margins — wellness, aesthetics, dentistry and veterinary practice — precisely because medicines sit awkwardly within the lenders' own risk appetite.
That produces the failure mode this cluster has now documented three times: the category described softly at onboarding, identified at volume, and terminated with settlement consequences. Any pharmacy that rejects this article's position and proceeds anyway inherits those mechanics unaltered. It needs written category acceptance from an FCA-authorised lender for medicines specifically, or nothing. The one-line filter does not soften because the product is credit rather than acquiring.
What are the cleaner architectures?
The need underneath the temptation is genuine: private treatment is expensive and affordability determines access. The answer lies in architecture, not lending.
Price per month of supply and collect as supplied. The subscription model this cluster has described — properly authenticated mandates, merchant-initiated billing — charges the patient for each month's medicine as it is dispensed. That delivers the monthly outlay the credit product advertises, with one structural difference that changes everything. The patient never owes for treatment not yet received, and stopping is a cancellation, not a default.
Commence with smaller quantities. Starter quantities and shorter first supplies cut the entry price honestly. They also suit titration clinically.
Permit pausing without penalty. Publish a hardship approach: the plan pauses, the review is kept, and where stopping would be clinically unwise the taper is planned with the prescriber. That treats payment failure as a clinical event presenting financially — which, in a medicines business, is what it is.
Signpost the NHS route. Where an NHS pathway exists, saying so costs a sale and buys legitimacy — which this site consistently argues is the sector's genuine asset.
None of this is charity. Monthly-collected plans convert the same financially stretched patient the credit product courts, at the same monthly price, without manufacturing a debtor. The pharmacy keeps a patient instead of acquiring a default.
What should be asked when the representative calls?
The approach will be made, by newly authorised firms carrying targets. Four questions end most of those conversations honestly.
First: will you confirm in writing that you accept prescription medicines specifically — not wellness or healthcare-adjacent categories — at our product mix? That is this cluster's standing filter, applied to credit. Second: what happens, precisely and contractually, when a patient defaults mid-course? Cover fees and collections conduct, and what your firm expects of us clinically while it pursues our patient. Third: who bears late-fee and default exposure on the treatment element, and is there any structure in which the answer is nobody? Fourth: what patient data flows to you at application and during servicing, on what lawful basis, and what do your models do with the fact that a person finances medicine? This site's data protection articles would ask that of any partner, and it carries unusual weight here.
A proposition that survives all four has earned the meeting. In the author's observation of adjacent markets, most end at the first question — which is its own answer.
What is the position?
This site's opinion, flagged as such and reached through the arguments above, is that pharmacy should not attach consumer credit to medicines. The arrival of regulation — welcome for the wider market — strengthens that position rather than weakens it. Respectable instalment credit will now approach healthcare carrying an authorisation certificate, and the sector needs its answer ready.
For operators who judge the question differently, the minimum honest threshold is demanding. It means an FCA-authorised lender post-Regulation-Day, written medicines-category acceptance, and affordability assessment observed rather than circumvented. It means no late-fee exposure on the treatment itself. And it means clinical decisions — reviews, tapers, whether to continue — kept structurally independent of the patient's standing with the finance partner.
The better answer, though, is the unremarkable one from the section above. Price monthly, collect monthly, pause humanely — and let the lenders find a category where a missed payment costs someone a parcel rather than a treatment plan. Some checkout facilities are worth less than the conversions they buy.
Key takeaways
- Instalment credit became FCA-regulated deferred payment credit on 15 July 2026. That brings authorisation or temporary permission, affordability assessment, the Consumer Duty and checkout disclosure to a £13 billion market reaching one in five UK adults.
- Pharmacy's temptation rests on genuine arithmetic — treatment plans in monthly hundreds and measurable conversion gains — just as authorised lenders approach healthcare respectably.
- The central objection is entanglement: adherence acquires a repayment schedule, the financially stretched are recruited by construction, and a creditor enters the clinical relationship. A medicine on instalments is a treatment plan with a default clause.
- Regulation fixes the lending's conduct, not the category fit. 15 July changed the adjective, not the noun.
- Own-book instalment arrangements generally fall outside the new perimeter. That makes them the greater difficulty, not an opportunity: full entanglement, no guardrails, and professional-standards exposure intact.
- Providers' own category rules have historically restricted medicines. Any operator proceeding anyway needs written medicines-specific acceptance from an authorised lender — this cluster's standing filter.
- The cleaner architecture already exists: per-month pricing collected as supplied, starter quantities, penalty-free pausing and NHS signposting. It delivers affordability through structure rather than debt.
Sources and further reading
FAQs
Monthly plans without the default clause.
The cleaner architecture in this article is buildable today: per-month treatment plans on properly flagged recurring billing, pause and taper handling wired to the clinical record, no lender in the loop. Our publisher builds those checkouts and Dataforge PMR runs the plans behind them. If affordability is the problem you are solving, see how it works before you solve it with credit.
See Dataforge PMR